LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Sarah Cannon Research Institute
Nashville, Estados UnidosPublicaciones en colaboración con investigadores/as de Sarah Cannon Research Institute (17)
2024
-
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 180-191
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
-
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study
Future oncology (London, England), Vol. 20, Núm. 6, pp. 297-306
2022
-
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer
Future oncology (London, England), Vol. 18, Núm. 28, pp. 3133-3141
-
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
ESMO Open, Vol. 7, Núm. 2
2019
2018
-
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Journal of Thoracic Oncology, Vol. 13, Núm. 2, pp. 165-183
-
Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)
Journal of Clinical Oncology
-
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Clinical Lung Cancer, Vol. 19, Núm. 4, pp. 331-339
2017
-
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
New England Journal of Medicine, Vol. 377, Núm. 20, pp. 1919-1929
-
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
Lung Cancer, Vol. 112, pp. 181-187
-
Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)
Journal of Clinical Oncology
-
Results from the Phase III Randomized Trial of Onartuzumab plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
Journal of Clinical Oncology, Vol. 35, Núm. 4
2016
-
Clinicopathologic features of advanced squamous NSCLC
Journal of Thoracic Oncology, Vol. 11, Núm. 9, pp. 1411-1422
-
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment
Journal of Thoracic Oncology, Vol. 11, Núm. 12, pp. 2066-2081
2013
-
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement
Cancer Discovery, Vol. 3, Núm. 4, pp. 406-417
2012
-
Treatment rationale study design for the MetLung trial: A randomized, double-blind phase III study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV met-positive non-small-cell lung cancer
Clinical Lung Cancer, Vol. 13, Núm. 6, pp. 500-504